Effect of traditional Uyghur medicine abnormal Savda Munziq extract on rabbit platelet aggregation in vitro and rat arteriovenous shunt thrombosis in vivo.

OBJECTIVE: Abnormal Savda Munziq (ASMq) is a standard herbal preparation used in Uyghur traditional medicine to fight chronic diseases including cardiovascular, but its specific effects on thrombosis and platelet aggregation are unknown. METHODS: Rabbit platelets were incubated with ASMq extract (10, 20, 40 µg/ml) for 15, 30, or 60 min, and aggregation was induced with ADP and collagen. In vivo, ASMq extract 2.97 g/kg, 5.94g/kg, 11.88 g/kg per os daily for 15 days were tested on thrombus wet weight in a rat model of arterio-venous bypass thrombosis. Plasma thromboxane B2 (TXB2) and 6-keto-PGF1a (6PG) were measured by radioimmunoassay. Aspirin (12 µg/ml and 5mg/kg) and saline were used as control in both experiments. RESULTS: ASMq inhibited ADP and collagen-induced aggregation in vitro in a dose-dependent manner that increased over time, to a maximum of 6.4 ± 1.3% and 21.6 ± 4.0% for ADP and collagen, respectively, at one hour׳s incubation with the highest concentration, whereas the effects of aspirin (34.5 ± 2.2% and 41.9 ± 2.5%, respectively) were stable over time. In vivo, ASMq inhibited thrombus formation dose-dependently, by 70% at the highest dose, compared to 67% with aspirin. ASMq essentially did not change prostaglandin production, compared to the clear inhibition by aspirin. CONCLUSION: Abnormal Savda Munziq extract inhibits dose-dependent platelet aggregation with ADP or collagen in vitro and thrombosis in vivo to values similar to those of aspirin, though unlike aspirin this effect does not seem mediated by an inhibition of cyclo-oxygenase.

Antihypertensive effects of Ocimum basilicum L. (OBL) on blood pressure in renovascular hypertensive rats.

Ocimum basilicum L. (OBL), sweet basil, is a medicinal herb used in traditional Chinese medicine to treat cardiovascular diseases including hypertension. The objective of the study was to investigate the possible antihypertensive effects of OBL extract in renovascular hypertensive rats. The two-kidney one-clip (2K1C) Goldblatt model of renovascular hypertension was used in Wistar rats. Rats were randomized into sham, untreated 2K1C, captopril- (30 mg kg(-1) per day orally) and OBL- (100, 200, 400 mg kg(-1) per day orally) (low (L)-, medium (M)-, high (H)-OBL) treated 2K1C groups (n=10-12 per group), followed up for 4 weeks. Blood pressure, heart weight/body weight, plasma angiotensin-II and endothelin (ET)-1 were studied. OBL reduced systolic and diastolic blood pressure by about 20 and 15 mm Hg, respectively, compared with 35 and 22 mm Hg for captopril, from the lowest dose tested with no dose dependency. Cardiac hypertrophy was reduced from 3.6+/-0.7 mg g(-1) for untreated 2K1C to 3.0+/-0.6, 2.9+/-0.6 and 2.4+/-0.4 mg g(-1) for L-, M- and H-OBL, respectively, compared with 2.6+/-0.5 for sham and 3.1+/-0.4 mg g(-1) for captopril (P<0.05). Renal function was improved with captopril. Angiotensin was reduced to a lesser extent than with captopril. ET was reduced to lower concentrations (78+/-15, 80+/-22, 82+/-15 pg ml(-1) for L-, M-, H-OBL, respectively) than in sham (116+/-31 pg ml(-1)), untreated 2K1C (174+/-72 pg ml(-1)) or captopril (117+/-72 pg ml(-1)) groups. The effects of OBL on blood pressure, cardiac hypertrophy and ET, are consistent with an effect on ET-converting enzyme, and warrant further exploration.